Search filters
Reimbursement Scheme Forxiga® (dapagliflozine) 10 mg for the treatment of HFpEF (LVEF >40%)

Reimbursement Scheme Forxiga® (dapagliflozine) 10 mg for the treatment of HFpEF (LVEF >40%)

27/02/2023

The health insurer does not yet fully reimburse Forxiga® (dapagliflozin) 10 mg for the treatment of HFpEF (LVEF >40%). The...

Reimbursement Scheme Isturisa®

Reimbursement Scheme Isturisa®

16/06/2022

The health insurer does not fully reimburse Isturisa® 1mg, 5mg and 10mg. The producer of this medicine has therefore asked TBR...

Termination TerugBetaalRegeling Forxiga® - Chronic Kidney Disease

Termination TerugBetaalRegeling Forxiga® - Chronic Kidney Disease

28/04/2022

From May 1st 2022 onwards, Forxiga® (dapagliflozine) 10 mg for the treatment of chronic kidney disease (CKD) is fully reimbursed...

Extension to TerugBetaalRegeling Elvanse®

Extension to TerugBetaalRegeling Elvanse®

01/04/2022

The health insurer does not fully reimburse Elvanse® 20 mg, 30 mg, 40 mg, 50 mg, 60 mg, and 70 mg. The manufacturer of this...

Reimbursement Scheme Ontozry® (12.5mg/25mg, 50 mg, 100 mg, 150mg)

Reimbursement Scheme Ontozry® (12.5mg/25mg, 50 mg, 100 mg, 150mg)

24/03/2022

The health insurer does not fully reimburse ONTOZRY® (12.5mg/25mg, 50 mg, 100 mg, 150mg). The producer of this medicine has...

You are currently offline. Some pages or content may fail to load.